This stock could be at the forefront of a leading narcolepsy treatment that can send its shares soaring, according to Morgan Stanley.
Centessa Pharmaceuticals could be at the forefront of a leading narcolepsy treatment that can send its shares soaring, according to Morgan Stanley. Analyst Jeffrey Hung upgraded the clinical-stage pharmaceutical company to overweight from equal weight. He also lifted his 12-month price target by $15 to $26, which suggests a whopping 64% potential upside. Shares are up nearly 108% this year and rose more than 5% Friday on the upgrade.
mountain Centessa stock this year. Centessa is developing a pipeline of orexin receptor 2 agonists , which attempt to activate parts of the body involved with regulating sleep and wakefulness in the body. One of the company's drugs is ORX750 for the treatment of sleep-wake disorders, including narcolepsy type 1 and 2, or NT1 and NT2. The drug also aims to treat idiopathic hypersomnia, or IH.
Centessa Pharmaceuticals PLC Centessa Pharmaceuticals PLC Stock Markets Investment Strategy Biotech And Pharmaceuticals Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How investors could net a 60% return from this oil stock, according to Morgan StanleyThe Wall Street investment bank upgraded the Brazilian oil and gas producer to overweight.
Read more »
Counting down the top 60 senior recruits in the SEC footprint: Nos. 51-60The Super Southeast 60 is back! Today we start the countdown of the top 60 recruits in the SEC footprint
Read more »
This is the pet stock to own says Morgan StanleyThis is the pet stock to own says Morgan Stanley
Read more »
This Asian stock is a long-term AI winner at attractive valuation: Morgan StanleyThis Asian stock is a long-term AI winner at attractive valuation: Morgan Stanley
Read more »
Avoid this popular travel stock says Morgan StanleyAvoid this popular travel stock says Morgan Stanley
Read more »
Morgan Stanley is bullish on this major Indian IT stockMorgan Stanley is bullish on this major Indian IT stock
Read more »